Nabil A. Elshourbagy1*, Harold Meyers1, Sherin S Abdel-Meguid1, Kavitha Godugu2, Taher A Salaheldin2, Dhruba J Bharali2 and Shaker A Mousa2
Received:April 28, 2021; Published: May 5, 2021
Corresponding author: Nabil A. Elshourbagy, Shifa Biomedical Corporation, 1 Great Valley Parkway, Suite 8, Malvern, PA 19355, USA
DOI: 10.32474/ACR.2021.03.000167
To view the Full Article Peer-reviewed Article PDF
PCSK9 is a well validated target for the treatment of hypercholesterolemia. Several pharmaceutical companies focused on the development of injectable monoclonal antibodies. Shifa Biomedical has focused on developing orally bioavailable small molecule PCSK9/LDLR antagonists. PCSK9 antagonists were identified through virtual screening at the PCSK9 surface where the LDLR-EGF-A binds. An SAR study of many analogues were done for their ability to antagonize the PCSK9/LDLR interaction in an in vitro ELISA assay, upregulate the LDLR in a cell-based assay, and increase LDL uptake in a fluorescent Dil-LDL assay. The most potent compound meeting these criteria was P-4, formulated by a nanocrystal/targeted delivery approach for the in vivo studies. Nano formulated P-4 was named P-21. P-4 exhibited a concentration-dependent inhibition of the PCSK9/LDLR interaction with an IC50 in the nanomolar range, an increase in the level of LDLR in recombinant cell-based assays, and a significant increase in the fluorescently labeled DiILDL uptake in the nanomolar range. P-4 also exhibited a good safety profile as demonstrated in vitro and in in vivo animal models. P-21 showed improved PK and PD of P-4. Oral administration of P-21 at 1, 3, 10, and 30 mg/kg in C57BL/6 mice fed a high-fat diet resulted in approximately a 20, 40, 60, and 90% LDL-C lowering, respectively. The identification of a small molecule orally bioavailable antagonist against PCSK9 could lead to a new class of therapies to treat hypercholesterolemia, especially for those patients that are statin resistant or stain intolerant.
Keywords: Atherosclerosis; low-density lipoprotein cholesterol; PCSK9 small molecule inhibitors; hypercholesterolemia; cholesterol
Abbreviations: AHA: American Heart Association; CETP: cholesteryl ester transfer protein; DHA: docosahexaenoic acid; DLS: dynamic light scattering; EC50: effective concentration ; EPA: eicosatetraenoic acid; ELS: electrophoretic light scattering; HPMC-AS: Hydroxypropyl methylcellulose acetate succinate; LDL-C: low-density lipoprotein-cholesterol; LDLR-EGFA-A: low-density lipoprotein receptor epidermal growth factor homology domain A; LDLR: low-density lipoprotein receptor; PCSK9: proprotein convertase subtilisin-like kexin type 9; PEG: polyethylene glycol; PLGA: poly-(lactic-co-glycolic acid) PK: pharmacokinetics; PD: pharmacodynamics ; SLN: solid lipid nanoparticle
Abstract| Introduction| Material and Methods| Statistical Analysis| Results| Discussion| References|
Bio chemistry
University of Texas Medical Branch, USADepartment of Criminal Justice
Liberty University, USADepartment of Psychiatry
University of Kentucky, USADepartment of Medicine
Gally International Biomedical Research & Consulting LLC, USADepartment of Urbanisation and Agricultural
Montreal university, USAOral & Maxillofacial Pathology
New York University, USAGastroenterology and Hepatology
University of Alabama, UKDepartment of Medicine
Universities of Bradford, UKOncology
Circulogene Theranostics, EnglandRadiation Chemistry
National University of Mexico, USAAnalytical Chemistry
Wentworth Institute of Technology, USAMinimally Invasive Surgery
Mercer University school of Medicine, USAPediatric Dentistry
University of Athens , GreeceThe annual scholar awards from Lupine Publishers honor a selected number Read More...